NVO to 107 USDTechnical Analysis Summary – NVO
After a prolonged downtrend, the stock established a potential reversal structure:
Wave 1: Initial impulsive rally, marking the first significant move against the prevailing bearish trend.
Wave 2: Healthy corrective pullback that retraced precisely to the 61.8% Fi
NOVO NORDISK A/S
1,285.00MXND
0.000.00%
Last update at Jun 26, 16:17 GMT
MXN
No trades
Key facts today
Novo Nordisk applied for EU approval of a new 7.2 mg Wegovy dose for obesity. Trials show a 21% average weight loss, with one-third losing 25% or more.
Novo Nordisk ended its partnership with Hims & Hers on June 23, 2025, over safety concerns regarding Wegovy, leading to a 5.5% drop in its stock.
Next report date
—
Report period
Q2 2025
EPS estimate
17.84 MXN
Revenue estimate
228.88 B MXN
69.73 MXN
291.41 B MXN
837.97 B MXN
3.16 B
About NOVO NORDISK B A/S
Sector
Industry
CEO
Lars Fruergaard Jørgensen
Website
Headquarters
Bagsværd
Founded
1931
ISIN
DK0062498333
FIGI
BBG01292CB39
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
25%
29%
33%
37%
41%
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
0.00
70.00 B
140.00 B
210.00 B
280.00 B
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
0.00
60.00 B
120.00 B
180.00 B
240.00 B
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
0.00
60.00 B
120.00 B
180.00 B
240.00 B
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
−120.00 B
0.00
120.00 B
240.00 B
360.00 B
Debt
Free cash flow
Cash & equivalents
No news here
Looks like there's nothing to report right now
$NVO Trade Idea – Potential Bullish Reversal Setup📊 Market Structure Insight
After a clear downtrend marked by consecutive Lower Highs (LH) and Lower Lows (LL), NYSE:NVO is beginning to show early signs of a trend reversal.
🔹 Recent price action has shifted into a Higher High (HH) and Higher Low (HL) formation – a classic sign of bullish momentu
NLong

NOVO expected to reach ATH during 2026Based on EW count and general knowledge about the company, it is expected that Novo will get back to the top (approx x2 from here) during 2026. Lets see
OLong

NVO Soaring Towards TargetsOur NVO call debit spreads and LEAPS options soaring towards targets at the 233 EMA here.
Beautiful thing when fundamentals, valuations and technicals align.
Impulse move from the bottom gave us a hat trick - triple green tags (white circles) for bullish A+ momentum signals into a consolidation p
NLong

NOVO is looking at a strong bullish bottoming outNYSE:NVO is looking at a strong bullish reversal and is likely to head higher after stochastic shows overbought AND long term stochastic shows clear confirmation of oversold crossover.
Price action shows a clear break out of the downtrend line and with the rounding bottom, the stock is likely to
NLong

NVO bounce off of Ozempic launch AVWAPOzempic launched Feb 5 2018. Anchoring our VWAP to that date we get our confirmation of a strong anchor from the COVID bounce, indicating institutional buying at that level. Over 7 years later, we get another opportunity.
NLong

Novo Nordisk: Massive buying opportunityNovo has been struggling big time, december and march hit especially hard.
American institutions have held large positions in Novo, and this was felt when they had to sell off due to risk management with the looming tariffs.
However, the sheer devaluation & importance of their export, is going to
OLong

nvo bullish long Long Setup Idea – Not Financial Advice - AH
This is a long trade setup based on my personal analysis.
The entry, stop-loss, and target levels are outlined for educational and illustrative purposes only.
📈 Entry:
🛑 Stop Loss:
🎯 Target(s):
Disclaimer:
I am not a financial advisor. This idea i
NLong

NVO Exhibits High Monthly Volume Amid Downtrend – SHortNVO Exhibits High Monthly Volume Amid Downtrend – Potential Accumulation Phase
📉 Post:
Novo Nordisk (NVO) has experienced a significant decline from its 52-week high of $148.15 to a recent low of $57.00. However, the monthly chart reveals an unusually high trading volume, which may indicate accumul
The most profitable drug known to man. Liquid goldThe title speaks for itself self.
Weekly RSI retesting a 10yr low.
Ozempic (GLP1) is and will continue to be the most profitable drug known to man.
NLong

See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
XS234803042
NOVO NO.F.NL 21/28Yield to maturity
2.38%
Maturity date
Jun 4, 2028
XS244933017
NOVO NO.F.NL 22/27MTNYield to maturity
2.25%
Maturity date
Sep 30, 2027
See all NOVOB/N bonds
Curated watchlists where NOVOB/N is featured.
Frequently Asked Questions
The current price of NOVOB/N is 1,285.00 MXN — it hasn't changed in the past 24 hours. Watch NOVO NORDISK A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange NOVO NORDISK A/S stocks are traded under the ticker NOVOB/N.
NOVOB/N stock has fallen by −10.25% compared to the previous week, the month change is a 1.35% rise, over the last year NOVO NORDISK A/S has showed a −42.36% decrease.
We've gathered analysts' opinions on NOVO NORDISK A/S future price: according to them, NOVOB/N price has a max estimate of 2,633.56 MXN and a min estimate of 1,024.16 MXN. Watch NOVOB/N chart and read a more detailed NOVO NORDISK A/S stock forecast: see what analysts think of NOVO NORDISK A/S and suggest that you do with its stocks.
NOVOB/N stock is 0.13% volatile and has beta coefficient of 1.43. Track NOVO NORDISK A/S stock price on the chart and check out the list of the most volatile stocks — is NOVO NORDISK A/S there?
Today NOVO NORDISK A/S has the market capitalization of 5.73 T, it has decreased by −4.21% over the last week.
Yes, you can track NOVO NORDISK A/S financials in yearly and quarterly reports right on TradingView.
NOVO NORDISK A/S is going to release the next earnings report on Aug 6, 2025. Keep track of upcoming events with our Earnings Calendar.
NOVOB/N earnings for the last quarter are 19.38 MXN per share, whereas the estimation was 18.12 MXN resulting in a 6.95% surprise. The estimated earnings for the next quarter are 17.84 MXN per share. See more details about NOVO NORDISK A/S earnings.
NOVO NORDISK A/S revenue for the last quarter amounts to 231.80 B MXN, despite the estimated figure of 231.36 B MXN. In the next quarter, revenue is expected to reach 228.88 B MXN.
NOVOB/N net income for the last quarter is 86.19 B MXN, while the quarter before that showed 81.46 B MXN of net income which accounts for 5.80% change. Track more NOVO NORDISK A/S financial stats to get the full picture.
NOVO NORDISK A/S dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jul 8, 2025, the company has 76.3 K employees. See our rating of the largest employees — is NOVO NORDISK A/S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO NORDISK A/S EBITDA is 465.55 B MXN, and current EBITDA margin is 50.95%. See more stats in NOVO NORDISK A/S financial statements.
Like other stocks, NOVOB/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO NORDISK A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO NORDISK A/S technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO NORDISK A/S stock shows the strong sell signal. See more of NOVO NORDISK A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.